Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals
NBS for SMA was dominant compared with no NBS for SMA in Australia from a state and territory payer perspective. Universal implementation of NBS for SMA would support access equity, as well as early diagnosis and treatment in infants with SMA, potentially leading to improved outcomes.
Authors
- Eppie M. Yiu (ORCID: https://orcid.org/0000-0001-6704-8402)
- Colman B Taylor (ORCID: https://orcid.org/0000-0003-1034-0191)
- Didu Kariyawasam (ORCID: https://orcid.org/0000-0002-4176-4010)
- Damian Clark
- Matthias Bischof (ORCID: https://orcid.org/0000-0003-1811-6709)
- Maina Kava (ORCID: https://orcid.org/0000-0002-0212-8468)
- Nicholas Smith (ORCID: https://orcid.org/0000-0003-2409-9239)
- A. Peacock (ORCID: https://orcid.org/0009-0006-2279-4317)
- Ian R. Woodcock (ORCID: https://orcid.org/0000-0002-4902-034X)
- Jane Adams
Institutions
- Novartis (Switzerland) (CH)
- New South Wales Department of Health (AU)
- The University of Melbourne (AU)
- The University of Western Australia (AU)
- Women's and Children's Hospital (AU)
- UNSW Sydney (AU)
- The George Institute for Global Health (AU)
- Novartis (Australia) (AU)
- Sydney Children’s Hospitals Network (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1007/s40120-025-00744-8
- Citations
- 2
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Novartis Pharma